BTG3 and non-small cell lung carcinoma: Toi et al.23retrospectively analyzed 137 patients with NSCLC and found out that individuals with preexisting antibodies (ANA, rheumatoid factor, antithyroglobulin, antithyroid peroxidase) at treatment initiation had more favorable outcome as indicated by PFS as compared to patients without antibodies.23